pharmacyte biotech, inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the united states. its cellular therapies are developed based on cell-in-a-box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. the company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. it is also developing a therapy for type 1 diabetes and insulin-dependent type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. pharmacyte biotech, inc. has a research agreement with the university of technology, sydney to create a version of melligen cells to treat diabetes; and a research agreeme
Company profile
Ticker
PMCB
Exchange
Website
CEO
Kenneth L. Waggoner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EFOODSAFETY COM INC, NUVILEX, INC.
SEC CIK
Corporate docs
Subsidiaries
Viridis Biotech, Inc. • PharmaCyte Biotech Australia • PharmaCyte Biotech Europe Limited ...
IRS number
621772151
PMCB stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
27 Mar 24
ARS
2023 FY
Annual report to shareholders
27 Mar 24
10-Q
2024 Q3
Quarterly report
18 Mar 24
10-Q
2024 Q2
Quarterly report
15 Dec 23
8-K
Departure of Directors or Certain Officers
24 Nov 23
8-K
New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder value
15 Nov 23
8-K
Changes in Registrant's Certifying Accountant
9 Nov 23
EFFECT
Notice of effectiveness
2 Oct 23
CORRESP
Correspondence with SEC
27 Sep 23
S-3/A
Shelf registration (amended)
21 Sep 23
Latest ownership filings
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
3
FEMASYS INC
28 Nov 23
4
ROBERT WEINSTEIN
22 Nov 23
4
WAYNE REMELL WALKER
22 Nov 23
4
Carlos Trujillo
22 Nov 23
4
Joshua Silverman
22 Nov 23
4
JONATHAN SCHECHTER
22 Nov 23
4
Michael M Abecassis
22 Nov 23
SC 13D
FEMASYS INC
22 Nov 23
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 23 | Apr 22 | Apr 21 | Apr 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.43 mm | 73.43 mm | 73.43 mm | 73.43 mm | 73.43 mm | 73.43 mm |
Cash burn (monthly) | 412.42 k | 294.78 k | 469.84 k | 495.09 k | 661.45 k | 205.96 k |
Cash used (since last report) | 2.33 mm | 1.67 mm | 2.66 mm | 2.80 mm | 3.74 mm | 1.16 mm |
Cash remaining | 71.09 mm | 71.76 mm | 70.77 mm | 70.63 mm | 69.68 mm | 72.26 mm |
Runway (months of cash) | 172.4 | 243.4 | 150.6 | 142.7 | 105.4 | 350.9 |
Institutional ownership, Q2 2023
12.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 6 |
Closed positions | 8 |
Increased positions | 2 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 2.80 bn |
Total shares | 1.06 mm |
Total puts | 31.10 k |
Total calls | 4.40 k |
Total put/call ratio | 7.1 |
Largest owners | Shares | Value |
---|---|---|
Ayrton Capital | 276.99 k | $792.20 mm |
Geode Capital Management | 219.07 k | $626.55 mm |
Vanguard | 183.58 k | $525.04 mm |
Citadel Advisors | 64.91 k | $185.64 mm |
Equitec Proprietary Markets | 61.42 k | $175.65 mm |
Simplex Trading | 47.15 k | $134.00 k |
BLK Blackrock | 43.32 k | $123.89 mm |
Dimensional Fund Advisors | 29.30 k | $83.81 mm |
NTRS Northern Trust | 28.42 k | $81.27 mm |
Renaissance Technologies | 25.87 k | $74.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Nov 23 | Silverman Joshua | Stock Option Common Stock | Grant | Acquire A | No | No | 2.18 | 170,000 | 370.60 k | 170,000 |
20 Nov 23 | Schechter Jonathan | Stock Option Common Stock | Grant | Acquire A | No | No | 2.18 | 61,248 | 133.52 k | 61,248 |
20 Nov 23 | Michael M Abecassis | Stock Option Common Stock | Grant | Acquire A | No | No | 2.18 | 61,248 | 133.52 k | 61,248 |
20 Nov 23 | Carlos Trujillo | Stock Option Common Stock | Grant | Acquire A | No | No | 2.18 | 85,000 | 185.30 k | 85,000 |